Device Trial Radar · NCT05785832
A Randomized Trial Evaluating Control-IQ+ Technology in Adults With Type 2 Diabetes
Last checked: Nov 20, 2026Latest source record: May 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
319
Actual
Start
Jun 1, 2023
Primary completion
Sep 24, 2024
Study completion Sep 24, 2024
Sponsor
- Lead sponsor
- Tandem Diabetes Care, Inc.Public (TNDM)
- Sponsor type
- Industry
- Collaborators
- Jaeb Center for Health Research
- First posted
- Mar 27, 2023
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A randomized controlled trial (RCT) to assess the safety and efficacy of use of Control-IQ+ technology in adults with type 2 diabetes using basal-bolus insulin therapy.
Conditions
- Type 2 Diabetes Treated With Insulin
Interventions
t:slim X2 insulin pump with Control-IQ+ technology and Dexcom G6 CGMDevice
The t:slim X2 insulin pump with Control-IQ+ technology, used with the Dexcom G6 CGM.
Standard Therapy plus continuous glucose monitoring (CGM)Device
Standard therapy is continuation of pre-study basal-bolus insulin delivery method, plus use of Dexcom G6 CGM.
Primary outcomes
What the sponsor says the trial is designed to measure.
- HbA1cTime frame: 13 weeks
Locations
21 sites in 2 countries. Site status is shown where the registry gives one.
Hoag Memorial Hospital Presbyterian
Newport Beach, California
Emory University School of Medicine
Atlanta, Georgia
Rocky Mountain Clinical Research
Idaho Falls, Idaho
18 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.